98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/08164622.2023.2188175 | DOI Listing |
Cureus
August 2025
Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, GBR.
Objective To determine real-world clinical outcomes (including vision, anatomy and durability) of intravitreal faricimab (IVF) in year two (up to mean follow-up of 75 ± 15 weeks, range: 52-103 weeks) of treating diabetic macular oedema (DMO). Secondary objectives included assessing changes in diabetic retinopathy (DR) severity, the incidence of epiretinal proliferation (ERP)/epiretinal membrane (ERM), and safety. Methodology This is a single-centre retrospective observational study.
View Article and Find Full Text PDFAm J Ophthalmol Case Rep
September 2025
Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Purpose: To report two cases of macular exudations resulting from retinal arterial macroaneurysms (MaAs) refractory to focal photocoagulations that were treated with a new surgical technique including subretinal balanced saline solution (BSS) injection to dilute lipid-rich subretinal fluid (SRF) and facilitate absorption of the SRF, intentional retinal hole formation to direct SRF into the vitreous cavity, and laser photocoagulation posterior to the MaAs to prevent intraretinal fluid and SRF from reaching the fovea.
Observations: A 70-year-old man with macular edema (ME) refractory to anti-vascular endothelial growth factor (VEGF) therapy was referred to our hospital. Fundus examination showed retinal arterial MaAs and hard exudations.
Ophthalmol Sci
July 2025
Department of Ophthalmology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
Purpose: This study evaluates retinal volume in the macula and peripheral retina in patients with nonproliferative diabetic retinopathy (NPDR), with and without diabetic macular edema (DME), using widefield swept-source OCT (SS-OCT).
Design: Retrospective observational study.
Participants: A total of 98 eyes were included: 30 from patients with NPDR without DME (DME-), 38 from patients with NPDR with DME (DME+), and 30 from age- and sex-matched healthy controls.
Diabetes Res Clin Pract
September 2025
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Aims: To evaluate the association between intravitreal anti-VEGF therapy and lower extremity complications in diabetic eye disease (DED), and compare risks among ranibizumab, aflibercept, and bevacizumab.
Methods: This retrospective cohort study used a U.S.
Surv Ophthalmol
September 2025
Department of Surgery, Division of Ophthalmology, McMaster University, Hamilton, Ontario, Canada; Singapore Eye Research Institute, Singapore National Eye Center, Singapore. Electronic address:
This systematic review examines the prognostic value of baseline optical coherence tomography (OCT) biomarkers in predicting visual acuity (VA) outcomes for eyes with macular edema secondary to retinal vein occlusions (RVO) treated with anti-VEGF therapies, steroids, laser photocoagulation, or combination treatments. VA predictions at 6, 12, and 24 months post-treatment were assessed using a narrative synthesis approach and vote counting based on effect direction relative to a minimal clinically important difference. Certainty of evidence was evaluated using GRADE guidelines.
View Article and Find Full Text PDF